RBC Capital keeps a Buy rating and $82 price target on Cytokinetics (CYTK), saying the firm remains bullish on the stock following the ...
Hosted on MSN15h
The risks of our bear case have risen, says RBC's Lori CalvasinaLori Calvasina, RBC Capital Markets head of U.S. equity strategy, joins 'Squawk Box' to discuss the latest market trends, ...
RBC Capital analyst Michael Carroll maintained a Hold rating on Medical Properties (MPW – Research Report) on March 7 and set a price target of ...
Investing.com -- Galderma Group AG has been downgraded by RBC Capital Markets to "sector perform" from "outperform," ...
Fintel reports that on March 7, 2025, RBC Capital initiated coverage of GH Research (NasdaqGM:GHRS) with a Outperform ...
RBC Capital Markets Global Financial Institutions Conference Transcript March 5, 2025 11:20 AM ETCompany ParticipantsJohn Stern ...
Popular, Inc. (NASDAQ: BPOP) announced today that it will participate in the upcoming RBC Capital Markets Global Financial ...
Private equity firm Bain Capital is weighing options, including a sale, for Rocket Software that could value the U.S.
Chinese authorities are rolling out fresh measures to limit capital flight, including increased scrutiny of overseas ...
All of those things need to be taken, I think, from a deeply analytical approach in terms of the implications, not just on capital but on banks' willingness to drive growth and to lend and ...
Coloplast (CSE: COLOb) has been upgraded to an "outperform" rating by RBC Capital Markets, with analysts citing a positive risk-reward balance and a price target increase to DKK 940 per share from DKK ...
RBC Capital raised the firm’s price target on AdaptHealth (AHCO) to $14 from $11 and keeps an Outperform rating on the shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback